SCHEMBL5656969

SCHEMBL5656969

COC(=O)[C@H](CSC(C)=O)NC(C)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
NFKB1 P19838 1/20 0.38
PTGS2 P35354 1/20 0.38
THPO P40225 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 1/20 0.37
ITGB1 P05556 1/20 0.36
ITGA4 P13612 1/20 0.36
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA3 P07451 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6470507 1.00 KDM4E (0.38) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL9966095 1.00 KDM4E (0.38) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL2294810 0.85 CYP1A2 (0.42) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL4879818 0.85 CYP1A2 (0.42) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL8739588 0.84 GAA (0.42) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL2872923 0.84 ITGB1 (0.48) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL2873174 0.84 ITGB1 (0.48) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL2408947 0.84 ITGB1 (0.48) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL9688310 0.84 GAA (0.42) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL5801290 0.84 MAPT (0.35) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12350250-B2 Aggrelytes for treating ocular conditions THE REGENT OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2025-07-08 US claimed
US-20240115538-A1 AGGRELYTES FOR TREATING OCULAR CONDITIONS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2024-04-11 US claimed
US-20250332135-A1 Aggrelytes for Treating Ocular Conditions UNIV COLORADO REGENTS (US) 2025-10-30 US disclosed
US-20250332135-A1 Aggrelytes for Treating Ocular Conditions UNIV COLORADO REGENTS (US) 2025-10-30 US disclosed
US-12350250-B2 Aggrelytes for treating ocular conditions THE REGENT OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2025-07-08 US disclosed
US-12350250-B2 Aggrelytes for treating ocular conditions THE REGENT OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2025-07-08 US disclosed
US-20240115538-A1 AGGRELYTES FOR TREATING OCULAR CONDITIONS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2024-04-11 US disclosed
US-20240115538-A1 AGGRELYTES FOR TREATING OCULAR CONDITIONS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2024-04-11 US disclosed
US-20120046232-A1 COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR MEDICAL UNIVERSITY OF SOUTH CAROLINA 2012-02-23 US disclosed
US-20120046232-A1 COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR MEDICAL UNIVERSITY OF SOUTH CAROLINA 2012-02-23 US disclosed
US-20060251597-A1 ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE YU RUEY J 2006-11-09 US disclosed
US-20050171194-A1 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions YU RUEY J (US) 2005-08-04 US disclosed
WO-2005055947-A2 ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS YU RUEY J (US) 2005-06-23 WO disclosed
US-6808716-B2 N-acetylamino acids, related N-acetyl compounds and their topical use YU RUEY J (US) 2004-10-26 US disclosed
WO-2004089329-A2 TOPICAL COMPOSITIONS COMPRISING N-ACETYLAMINO ACIDS OR RELATED N-ACETYL COMPOUNDS YU RUEY J (US) 2004-10-21 WO disclosed
US-6703031-B1 OXIDATIVE STRESS INHIBITOR; RETARDING AGING OF SKIN AJINOMOTO CO., INC. (JP) 2004-03-09 US disclosed
US-20030229141-A1 N-acetyl cysteine and its topical use YU RUEY J (US) 2003-12-11 US disclosed
US-20030198656-A1 N-acetylamino acids, related N-acetyl compounds and their topical use YU RUEY J (US) 2003-10-23 US disclosed
US-6602492-B2 Cysteine derivatives AJINOMOTO CO., INC. (JP) 2003-08-05 US disclosed
EP-1120407-A1 CYSTEINE DERIVATIVES Ajinomoto Co., Inc. (JP) 2001-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046232-A1 COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR GRM6, GRM5, GRM7 KDM4E 1271/4885MAPT 3237/4885THRB 1739/4885
US-20250332135-A1 Aggrelytes for Treating Ocular Conditions AADAC, MGMT, MGST3 KDM4E 3225/4885MAPT 375/4885THRB 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.